Previously, loss of FHIT expression in cancer has been found to mirror other poor prognosis markers, being positively correlated with Bcl-2 and p53 overexpression, proliferative activity and aggressive histological phenotype and negatively correlated with oestrogen and progesterone receptor status (Campiglio et al, 1999; Yang et al, 2001; Arun et al, 2005). This evidence concerns the gene TP53 and cancer.